Related Experiment Video

Updated: Apr 20, 2026

A Modified QuEChERS-HPLC Method for Detection of Polycyclic Aromatic Hydrocarbons in Zebrafish Embryos Exposed to Fine Particulate Matter
04:39

A Modified QuEChERS-HPLC Method for Detection of Polycyclic Aromatic Hydrocarbons in Zebrafish Embryos Exposed to Fine Particulate Matter

Published on: June 13, 2025

871

Interaction between paraoxonase 1 polymorphism and prenatal pesticide exposure on metabolic markers in children using

Anne Jørgensen1, Christine Nellemann2, Christine Wohlfahrt-Veje3

  • 1Institute of Public Health, University of Southern Denmark, Odense, Denmark; University Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark.

Reproductive Toxicology (Elmsford, N.Y.)
|December 3, 2014
PubMed

Insights

Prenatal pesticide exposure impacts children's cardio-metabolic health, particularly for those with the paraoxonase1 (PON1) R-allele. This genetic factor influences how pesticide exposure affects metabolic markers and body fat accumulation.

Area of Science:

  • Environmental Health
  • Metabolic Diseases
  • Genetics

Background:

  • Prenatal environmental exposures are linked to later-life cardio-metabolic disease risk.
  • The paraoxonase1 (PON1) Q192R genotype modulates susceptibility to environmental insults.
  • Previous studies indicated genotype-dependent associations between prenatal pesticide exposure, body fat, and blood pressure.

Purpose of the Study:

  • To investigate serum metabolic markers in relation to prenatal pesticide exposure in school-aged children.
  • To examine the role of the PON1 Q192R genotype in mediating these associations.
  • To identify specific metabolic pathways affected by prenatal pesticide exposure.

Main Methods:

  • Multiplex analysis of non-fasting serum metabolic markers.
  • Cohort study of school-aged children with detailed prenatal exposure data.
  • Stratification analysis based on PON1 Q192R genotype (R-allele carriers vs. QQ-homozygotes).

Main Results:

  • In children with the PON1 R-allele, leptin, glucagon, and plasminogen activator inhibitor-1 (PAI-1) were positively associated with prenatal pesticide exposure.
  • No significant associations were observed between prenatal pesticide exposure and these biomarkers in QQ-homozygote children.
  • Leptin mediated the association between prenatal pesticide exposure and body fat accumulation in R-allele carriers.

Conclusions:

  • Prenatal pesticide exposure is associated with an adverse cardio-metabolic risk profile in children carrying the PON1 R-allele.
  • The PON1 Q192R genotype is a critical determinant of individual susceptibility to prenatal pesticide effects.
  • Findings highlight the importance of genetic factors in environmental health research and disease prevention.

Keywords:
Environmental obesogensGlucagonLeptinPAI-1Pesticides, Prenatal exposure, PON1 genotype

More Related Videos

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

8.7K
A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites13:35

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

Published on: March 1, 2018

15.5K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
373
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
286
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
83
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
170
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
927
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135